Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT02899728 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Extensive Stage Lung Small Cell Carcinoma

Interventions

DRUG: Carboplatin
DRUG: Cediranib
DRUG: Cediranib Maleate
DRUG: Cisplatin
DRUG: Etoposide
DRUG: Olaparib

Sponsor

National Cancer Institute (NCI)